Deep biology, translated into strategy.
Partner-led scientific strategy for biotech, spinout, and investor teams — anchored in metabolic disease, and built to turn mechanism, evidence, and market dynamics into clear development, biomarker, and positioning decisions.
How we think
Deep science only creates value once it is translated into a decision. Deep BioStrategy works at that seam — reading the biology, grading the evidence, and ending in a defensible call.
Mechanism-aware
We read the biology, not just the headline.
Evidence-graded
We separate approved indications from trial findings and emerging frontiers, and label each clearly.
Decision-oriented
Every analysis is built to support a strategic decision, not produce a literature dump.
Insights and Reports
Two ways we think in public — narrative perspective, and evidence-graded analysis. They are different formats for different needs.
Insights
Narrative essays on where science, medicine, and strategy are moving.
Featured: The Translational Gap in Metabolic Disease
Read the essay → Evidence / AnalysisReports
Structured, evidence-graded analyses for biotech, BD, investors, and translational teams.
Featured: GLP-1 and Incretin Therapeutics
Read the report →A companion metabolism market report is in development.
Who we help
Biotech founders
Preparing for fundraising, platform positioning, or strategic inflection points where the science needs to hold up under scrutiny.
Academic spinouts
Translating discoveries into investable stories, credible development plans, and clear scientific narratives.
Investors & BD teams
Needing independent scientific diligence, landscape analysis, or KOL-informed perspective on early-stage opportunities.
Medtech-adjacent teams
Working at the intersection of metabolic disease, clinical workflow, digital health, and physician adoption.
What we deliver
Strategic Scientific Memo
Hypothesis-driven analysis for board, investor, or internal decision-making — the signature deliverable, supported by diligence, landscape, KOL, narrative, spinout, and retainer services.
Metabolic disease is our center of gravity.
Our work is anchored in metabolic disease because it is where deep biology, clinical evidence, and strategic urgency now converge. We think across diabetes, obesity, incretin and islet biology, MASH/MASLD, chronic kidney disease, cardiometabolic organ protection, biomarkers, translational endpoints, and therapeutic positioning.
When a question reaches beyond metabolic disease, Deep BioStrategy can draw on a focused advisory bench for adjacent scientific, behavioral, legal/commercial, and translational perspectives.
Explore metabolic strategy →Partner-led scientific strategy
Deep BioStrategy is partner-led by Ivan A. Valdez, PhD and Alfred Atallah, JD, combining metabolic-science depth with biotech business and transaction-informed judgment. Ivan brings Harvard-trained biomedical science and healthcare strategy experience; Alfred brings a JD-trained business and client-facing perspective shaped across biotech, biopharma, venture, and strategic advisory contexts.
Meet the partners →Specialized expertise, engaged by scope
Deep BioStrategy is partner-led by Ivan A. Valdez, PhD and Alfred Atallah, JD. When a scoped question calls for complementary expertise, specialized advisors may contribute perspective across clinical strategy, commercialization, neuroscience, cancer biology, and biomedical science.
See the advisory bench →Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]